Valeant Pharmaceuticals International (VRX)
Valeant Pharmaceuticals International Revenue Growth: 51.52%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VRX Revenue Growth Rankings
| Overall | 92nd percentile | 325 of 4363 |
| Sector | 85th percentile | 64 of 457 in Healthcare |
| Industry | 70th percentile | 3 of 10 in Drug Delivery & Accessories |
VRX Revenue Growth Range, Past 5 Years
| Minimum | -34.76% | Sep 2007 |
| Maximum | 188.4% | Sep 2011 |
| Average | 32.89% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these VRX related companies
VRX News
Jeffrey Ubben's ValueAct Capital has bought around 1.5m shares of $VRX over past month (via various SEC Form 4's). Owns 17.1m shares now
about 2 days ago by marketfolly
about 2 days ago by marketfolly
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 http://stks.co/3yvG #corpgov
about 8 days ago by corpgovnet
about 8 days ago by corpgovnet
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 New Information #corpgov
about 8 days ago by corpgovnet
about 8 days ago by corpgovnet
Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal for C$28M
May 24, 7:58AM Benzinga
May 24, 7:58AM Benzinga
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 50 http://stks.co/3xWY #corpgov #VRX #Valeant
about 9 days ago by corpgovnet
about 9 days ago by corpgovnet
Yet Another Solid Momentum Value Stock Portfolio Beating S&P 500 Handily http://stks.co/3v8r $MA $ORLY $TJX $AAP $VRX
about 11 days ago by tailwind
about 11 days ago by tailwind
Momentum on value stocks: beating S&P by big margin http://stks.co/3t6S $ORLY $GOOG $MA $VRX $TJX $AAP
about 14 days ago by tailwind
about 14 days ago by tailwind
Boxer Shorts include $FSLR and $VRX. Look for the next move in VRX to be down around 46. Video at http://stks.co/3rGp
about 16 days ago by thetechtrader
about 16 days ago by thetechtrader
Top 4 Stocks In The Drug Delivery Industry With The Highest Operating Margin
May 07, 2:10AM Benzinga
May 07, 2:10AM Benzinga
$VRX http://stks.co/3geT An engulfing bearish reversal bar Thursday on heavy volume - look to short on any bounce
about 27 days ago by TraderFlorida
about 27 days ago by TraderFlorida
$VRX big engulfing day a couple sessions ago. Huge volume. Looks ready to go lower http://stks.co/3gcq
about 27 days ago by financialtrader
about 27 days ago by financialtrader
$VRX Exactly why I never buy pharma stocks. This kind of crap happens so often it's prophetic.
about 29 days ago by IncrementalWealth
about 29 days ago by IncrementalWealth
News related to $VRX, currently -9.9% since open: 'Valeant posts 1Q loss on dermatology deal costs' http://stks.co/3eWN
about 29 days ago by TradeBot
about 29 days ago by TradeBot
$VRX getting killed after earnings release, breaking down below 50 day MA. I never found their EPS release schedule.
about 29 days ago by Global_Trader
about 29 days ago by Global_Trader
Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook
May 03, 8:10AM Street Insider
May 03, 8:10AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VRX | 48.66 | +0.74 | +1.54% | 14.92B |
| VRTX | 60.04 | -0.14 | -0.23% | 12.63B |
| VRTS | 70.88 | +0.51 | +0.72% | 545.78M |
| VRTB | 1.260 | -0.00 | -0.01% | 16.56M |
| VRTA | 1.10 | -0.04 | -3.51% | 6.974M |
| VRSN | 38.23 | -0.39 | -1.01% | 6.098B |
| VRSK | 47.90 | +0.01 | +0.02% | 7.893B |
| VRS | 1.15 | +0.04 | +3.60% | 60.48M |
| VRNT | 28.72 | -0.32 | -1.10% | 1.116B |
| VRNM | 3.58 | +0.16 | +4.68% | 45.14M |
